Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased small conductance calcium-activated potassium type 2 channel-mediated negative feedback on N-methyl-D-aspartate receptors impairs synaptic plasticity following context-dependent sensitization to morphine.
Fakira AK, Portugal GS, Carusillo B, Melyan Z, Morón JA. Fakira AK, et al. Among authors: melyan z. Biol Psychiatry. 2014 Jan 15;75(2):105-14. doi: 10.1016/j.biopsych.2013.04.026. Epub 2013 Jun 2. Biol Psychiatry. 2014. PMID: 23735878 Free PMC article.
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
Faraone SV, Gomeni R, Hull JT, Chaturvedi SA, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Faraone SV, et al. Among authors: melyan z. Psychiatry Res. 2022 Dec;318:114922. doi: 10.1016/j.psychres.2022.114922. Epub 2022 Oct 23. Psychiatry Res. 2022. PMID: 36375329 Free article. Clinical Trial.
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
Nasser A, Hull JT, Liranso T, Busse GD, Melyan Z, Childress AC, A Lopez F, Rubin J. Nasser A, et al. Among authors: melyan z. Neuropsychiatr Dis Treat. 2021 Jun 3;17:1751-1762. doi: 10.2147/NDT.S312011. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34113106 Free PMC article.
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, Rubin J, Nasser A. Faraone SV, et al. Among authors: melyan z. Paediatr Drugs. 2021 Nov;23(6):583-589. doi: 10.1007/s40272-021-00470-2. Epub 2021 Sep 15. Paediatr Drugs. 2021. PMID: 34523063 Free PMC article.
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, Rubin J, Nasser A. Faraone SV, et al. Among authors: melyan z. Eur Child Adolesc Psychiatry. 2023 Mar;32(3):491-499. doi: 10.1007/s00787-021-01877-5. Epub 2021 Sep 28. Eur Child Adolesc Psychiatry. 2023. PMID: 34581911 Free PMC article. Clinical Trial.
25 results